Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review

Since sorafenib was introduced in 2007 for treating advanced hepatocellular carcinoma (HCC), 15 patients have achieved a complete response (CR) in advanced HCC. However, only four of these reports can be regarded as real CRs involving adequate assessments including imaging, serum tumor markers, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae Suk, Kim, Ji Hoon, Kim, Baek hui, Lee, Young-Sun, Yoo, Yang Jae, Kang, Seong Hee, Suh, Sang-June, Jung, Young Kul, Seo, Yeon Seok, Yim, Hyung Joon, Yeon, Jong Eun, Byun, Kwan Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760007/
https://www.ncbi.nlm.nih.gov/pubmed/28633200
http://dx.doi.org/10.3350/cmh.2016.0070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760007/
https://www.ncbi.nlm.nih.gov/pubmed/28633200
http://dx.doi.org/10.3350/cmh.2016.0070

Ejemplares similares